Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Bone Marrow Diseases » Myeloproliferative Disorders
Description
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE. MeSH
Hierarchy View
Subtype Terms (8)
Leukemia, Erythroblastic, Acute
7 drugs (6 approved, 1 experimental)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
236 drugs (127 approved, 109 experimental)
Leukemia, Neutrophilic, Chronic
34 drugs (29 approved, 5 experimental)
Polycythemia Vera
102 drugs (60 approved, 42 experimental)
Primary Myelofibrosis
196 drugs (107 approved, 89 experimental)
Thrombocytosis
11 drugs (9 approved, 2 experimental)
Phase 4 Indicated Drugs (2)
Phase 3 Indicated Drugs (49)
Phase 2 Indicated Drugs (102)
allogeneic natural killer cells
autologous mesenchymal stem cells
autologous mononuclear stem cell
gemtuzumab ozogamicin (mylotarg)
human fecal microbiota (Reybota)
immune globulin (human) (Gamastan)
Other Experimental Indicated Drugs (16)
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (43)
Albert Einstein Israelite Hospital
Blood and Marrow Transplant Clinical Trials Network
Case Western Reserve University
Center for International Blood and Marrow Transplant Research
European Organisation for Research and Treatment of Cancer
Organization Involved with Phase 2 Indications (99)
Canadian Society of Hematology
Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network
Cancer Biotherapy Research Group
Cancer Treatment Centers of America
City of Hope National Medical Center
Groupe Francophone des Myelodysplasies
Hoag Memorial Hospital Presbyterian
Icahn School of Medicine at Mount Sinai
Innovative Therapies For Children with Cancer Consortium
Katholieke Universiteit Leuven
Korea Research Institute of Bioscience & Biotechnology
Memorial Sloan-Kettering Cancer Center
Myeloproliferative Neoplasms Research Consortium
National Institutes of Health (NIH)
Pavlov First Saint Petersburg State Medical University
service Hématologie Séniors Hôpital Saint Louis
Swiss Group for Clinical Cancer Research
Organization Involved with Phase 1 Indications (35)
Organization Involved with Other Experimental Indications (4)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
